Drug intelligence / Profile preview

zabinostat + anti-pd1

Development stage: Unknown
Lead developer: Celleron Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

Zabinostat + anti-PD1 is a combination therapy comprising zabinostat (CXD101), a selective class I histone deacetylase (HDAC) inhibitor, and a programmed cell death protein 1 (PD-1) blocking monoclonal antibody. Developed by Celleron Therapeutics (and its affiliate Tcellaron Therapeutics), the combination is designed to overcome immunotherapy resistance in "cold" tumors. Zabinostat acts as an epigenetic modulator that enhances the expression of immune-related genes, increases MHC class I and II molecules on tumor cells, and promotes the infiltration and activity of T lymphocytes and dendritic cells. This priming effect is intended to sensitize microsatellite-stable (MSS) colorectal cancer (CRC) and other refractory malignancies to PD-1 checkpoint inhibition. The combination has been investigated in Phase 2 and Phase 3 clinical trials, particularly for MSS CRC and B-cell lymphomas.

Other names: zabadinostat + anti-pd1CXD101 + anti-pd1zabinostat + pembrolizumabzabinostat + nivolumab

Targets

HDAC1 (Histone Deacetylase 1)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on zabinostat + anti-pd1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on zabinostat + anti-pd1.

Explore the full profile